Close
FINDING CURES TOGETHER<sup>SM</sup>

Melanoma: From Biology to Target

​Program

Tuesday, Jan. 15 

Friday, Jan. 18


Tuesday, Jan. 15

Welcome and Keynote Session
4-5 p.m.

Strategies for targeted and immune therapy in melanoma
Meenard Herlyn, The Wistar Institute, Philadelphia, Pennsylvania


Opening Reception
5-6:30 p.m.


Wednesday, Jan. 16

Continental Breakfast
7-8 a.m.


Plenary Session 1: Understanding Resistance to Checkpoint Blockade
Session Chair: Antoni Ribas, University of California, Los Angeles, California
8-10 a.m.

Targeting the TIGIT/CD226 axis in melanoma
Hassane M. Zarour, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Response and resistance to checkpoint blockade therapy
Antoni Ribas

Overcoming immune resistance with rationally designed combination immunotherapy
Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, New York

A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade*
Livnat Jerby-Arnon, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype*
Arthur Liu, The University of Texas MD Anderson Cancer Center, Houston, Texas



Break
10-10:30 a.m.


Plenary Session 2: Unique Biology of Melanoma
Session Chair: Michael A. Davies, The University of Texas MD Anderson Cancer Center, Houston, Texas
10:30 a.m.-12:30 p.m.

Distinct immune and molecular features of melanoma brain metastases
Michael A. Davies

Concepts of cancer and Metastasis: Historical perspective 
Claire Lugassy, Institut Curie, Paris, France

Impact of tumor-resident dendritic cells on anti-tumor immune responses
Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, Massachusetts

Non-genomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype*
Scott Woodman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis*
Douglas Hanniford, NYU Langone Health, New York, New York


Free Time (Lunch on Own)
12:30-2:30 p.m.


Plenary Session 3: Melanoma Metabolism
Session Chair: Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, New York
2:30-4:30 p.m.

Elevated endogenous SDHA drives pathological metabolism in highly metastatic uveal melanoma
Chandrani Chattopadhyay, The University of Texas MD Anderson Cancer Center, Houston, Texas

Tumor cell oxidative metabolism as a barrier to antitumor immunity in melanoma
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA

Targeting melanoma metabolism to overcome resistance to treatment
Paul B. Chapman

Unique lipid metabolite profiling in BRAFV600E inhibitor drug-resistant melanoma and their potential as drug target*
Meng-Ting Chang, Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan

The glutaminase inhibitor CB-839 potentiates anti-melanoma activity of standard-of-care targeted therapies and immunotherapies*
Vashisht Yennu Nanda, The University of Texas MD Anderson Cancer Center, Houston, Texas


Poster Session A / Reception
4:30-7 p.m.


Thursday, Jan. 17

Continental Breakfast
7-8 a.m.


Plenary Session 4: Early Melanoma Detection and Prevention
Session Chair: Sancy A. Leachman, Oregon Health & Science University, Portland, Oregon
8-10 a.m.

The war on melanoma: Oregon’s early detection experiment
Sancy A. Leachman

Preventing melanoma progression through a genomic approach
Marianne Berwick, University of New Mexico Health Sciences Center-Albuquerque, Albuquerque, New Mexico

Opportunities and challenges in melanoma early detection
David Polsky, New York University School of Medicine, New York, New York

The role of keratinocyte desmoglein 1 in shaping the melanoma tumor niche*
Hope Burks, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

Identifying the molecular and environmental factors mediating transformation of melanocyte stem cells to melanoma*
Andrew White, Cornell University, Ithaca, New York


Break
10-10:30 a.m.


Plenary Session 5: Non-Cutaneous Melanoma and Rare Cutaneous Subtypes
Session Chair: Richard D. Carvajal, Columbia University Medical Center, New York, New York
10:30 a.m.-12:30 p.m.

Immunosensitivity and resistance in advanced uveal melanoma
Richard D. Carvajal

Novel genomic and transcriptomic aberrations in acral compared to sun-exposed melanomas
Ruth Halaban, Yale University, New Haven, Connecticut
Kahn Rhrissorrakrai, IBM Thomas J. Watson Research Center, Yorktown Heights, NY

The landscape of mucosal melanoma: A long way to go
Jun Guo, Peking University Cancer Hospital & Institute, Beijing, China

Pharmacological targeting of Gq reveals new pathways in uveal melanoma*
Michael Onken, Washington University School of Medicine, Saint Louis, Missouri


Poster Session B / Lunch
12:30-3 p.m.


Plenary Session 6: Targeting Driver Pathways Beyond BRAF
Session Chair: Marcus W. Bosenberg, Yale University, New Haven, Connecticut
3-5 p.m.

Defining the actionable genome
David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York

Therapeutic opportunities gleaned from melanoma's unique pathogenesis
David E. Fisher, Massachusetts General Hospital, Boston, Massachusetts

Role of autophagy in cancer
Eileen P. White, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Identifying new immune targets in malignant melanoma
Marcus W. Bosenberg


Break
5-5:15 p.m.


Special Session: Proffered Talks from Highly Rated Abstracts
Session Chairs: Mario Sznol, Yale Cancer Center, New Haven, Connecticut, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York
5:15-6:30 p.m.

Understanding the role of myddosome dynamics in melanoma using live cell imaging*
Bridget Kreger, AstraZeneca, Waltham, Massachusetts

Regulation of the tumor suppressive miR-29 family by oncogenic MAPK signaling in melanoma*
Olga Vera, Moffitt Cancer Center, Tampa, Florida

PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas*
Minjung Kim, University of South Florida, Tampa, Florida

Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma*
Jaymes Farrell, Tufts University, Boston, Massachusetts

Monitoring of melanoma progression utilizing multi-platform biomarkers of blood cell-free DNA*
David Hoon, John Wayne Cancer Insitute, Santa Monica, California


Friday, Jan. 18

Continental Breakfast
7-8 a.m.


Plenary Session 7: Intersection of the Tumor and Immune Microenvironment
Session Chair: Suzanne L. Topalian, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
8-10 a.m.

Translating immunotherapy from melanoma to other skin cancers
Suzanne L. Topalian

Intrinsic tumor genomic and metabolic factors leading to immunoresistance
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Myeloid cell melanoma interface
Karolina Palucka, The Jackson Laboratory, Farmington, Connecticut

CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy*
Suhendan Ekmekcioglu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Specific activation of the G protein-coupled estrogen receptor inhibits melanoma and other cancers and potentiates immune and targeted therapies*
Todd Ridky, University of Pennsylvania, Philadelphia, Pennsylvania


Break
10-10:30 a.m.


Plenary Session 8: BRAF and MEK Resistance
Session Chair: Jeffrey A. Sosman, Northwestern University, Chicago, Illinois
10:30 a.m.-12:30 p.m.

Are there non-immune targets in the BRAFV600 WT melanoma patient?
Jeffrey A. Sosman

Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers
Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Strategies to overcome MAPK inhibitor resistance
Roger S. Lo, University of California, Los Angeles, California

Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma*
Christopher Stipp, University of Iowa, Iowa City, Iowa

Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance*
Vito Rebecca, Wistar Institute, Philadelphia, Pennsylvania
 

Closing Remarks
12:30-12:45 p.m.


*short talks from proffered abstracts



Top of page